Medication info
Divalton Tablet 160 mg (Valsartan)

Divalton Tablet 160 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›160mg / 1 tablet
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
Oval-shaped, orange film-coated tablet with a grayish tint
Packaging
30 tablets (10 tablets/PTP x 3), 100 tablets (10 tablets/PTP x 10)
Approval status
Active

MFDS item code 201107216 · Approved 2011.09.27 · Insurance code 648506620

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults with essential hypertension: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment, creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. Patients with renal impairment, creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment, creatinine clearance below 10 mL/min, and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Adults with heart failure: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. Adults to reduce the risk of death after myocardial infarction: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is used to control blood pressure in patients with essential hypertension. It is also helpful for patients with heart failure who are intolerant to ACE inhibitors, particularly those with NYHA classification from II to IV. It is effective in reducing the risk of death in patients with reduced left ventricular function after myocardial infarction. In summary, this medication is used for hypertension, heart failure, and reducing the risk of death after myocardial infarction.

How to take

Adult dose

Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults with essential hypertension: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be co-administered. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Elderly patients (75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment, creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. Patients with renal impairment, creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment, creatinine clearance below 10 mL/min, and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Adults with heart failure: The recommended initial dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When co-administering a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. Adults to reduce the risk of death after myocardial infarction: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. Over the following weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, co-administration with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is required if creatinine clearance is 10 mL/min or greater. However, because there is no experience with use in patients with creatinine clearance below 10 mL/min or in patients on dialysis, do not administer this medicine. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This medication should not be administered to pregnant or nursing women, patients with severe liver or kidney impairment, or those with hereditary angioedema. Caution should be exercised in elderly patients or those with specific conditions such as hyperkalemia or liver impairment; their condition should be closely monitored before and after administration. As this medication lowers blood pressure, it may cause a sudden drop in blood pressure upon initial use, leading to dizziness or fainting. During treatment, regular monitoring of blood pressure, kidney function, and blood potassium levels is necessary to ensure there are no abnormalities. When taken with other antihypertensive medications or diuretics, potassium supplements, etc., there is an increased risk of side effects due to interactions, so consulting a specialist is advisable. This medication may cause dizziness while driving or operating machinery, so caution is needed. In case of overdose, severe hypotension or decreased consciousness may occur, requiring immediate medical assistance. Safety for children and adolescents under 18 years has not been established, so use is not recommended. During storage, keep this medication out of reach of children and avoid transferring it to other containers.

Side effects

headache

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its effectiveness.

Appearance and packaging

Appearance

Oval-shaped, orange film-coated tablet with a grayish tint

Package unit

30 tablets (10 tablets/PTP x 3), 100 tablets (10 tablets/PTP x 10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.